Overview

NeuCyber NeuroTech (Beijing Xinzhida Neurotechnology) is a Chinese BCI company incubated in 2023 by the Chinese Institute for Brain Research (CIBR). The company develops both the Neucyber high-performance invasive BCI and the “Beinao No. 1” semi-invasive brain chip, positioning itself across the spectrum of invasive and semi-invasive approaches. The controlling shareholder is the Beijing municipal government’s state asset regulator.

Beinao Technology

The Beinao system uses a semi-invasive approach, placing electrodes on the brain surface without penetrating cortical tissue — similar in concept to electrocorticography (ECoG) but with proprietary advances in signal processing and wireless transmission. This balances signal quality against surgical risk.

Clinical Progress

NeuCyber achieved early clinical milestones with implantation in three patients in early 2025, with a stated target of 50 patients by 2026. The rapid clinical expansion reflects both the company’s development pace and the supportive Chinese regulatory environment for BCI trials.

Academic Foundation

The Tsinghua University partnership provides NeuCyber with deep neuroscience research capabilities and access to one of China’s premier engineering institutions. This academic-commercial collaboration follows the model established by BrainGate and Neuralink in the US.